KRON - Kronos Bio Inc Company Balance Sheet Assets

Symbol and logo of brand Kronos Bio Corp (KRON)

Kronos Bio, Inc. (KRON) maintains its status as a reputable player in oncology, having earned physician recognition for its methods of combating resistant neoplasms. The company is recognized as an expert in developing small-molecule compounds, leveraging deep analysis of transcription factors. This chart illustrates the market price of total assets, which stands at 145.55. The business is currently developing a precision approach, creating innovative drugs to target previously undruggable protein targets.

KRON: Kronos Bio Inc Aggregate Company Assets 07/04/2022 - 06/28/2025

Summary analytical data breakdowns for Kronos Bio Corp (KRON)

- price and consensus price forecast:
Share Price kronosbio.com|KRON - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Kronos Bio Corporation|KRON - Enterprise Value
- book capitalization data:
Net Asset Value per Share Kronos Bio|KRON - Company Book Value|Capitalization to Book Value Ratio kronosbio.com|KRON - Company Total Assets
- debt and liquidity data:
Debt to Capital Kronos Bio, Inc.|KRON - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Kronos Bio Corporation|KRON - Company Aggregate Debts|Debts to Book Capitalization Kronos Bio Corporation|KRON - Company Long-Term Debt|Company Short-Term Debt Kronos Bio
Fundamental valuation:kronosbio.com, KRON
Finished products of Kronos Bio Corporation

The trend of total resources for Kronos Bio, Inc. (KRON) on GURU.Markets reflects the scale of the company's expansion into targeted oncology through strategic alliances. This metric, calculated inversely via ROA, aggregates equity and liabilities to demonstrate the business's overall material base. While the growth of this metric confirms expanding scientific synergy, investors must distinguish organic asset growth from risky borrowing.

Main competitors

incyte.com (INCY) - Total Business Assets|HUTCHMED - Company Total Assets|Company Balance Sheet Assets Nuvation Bio Inc|Day One Bio - Company Total Assets|Company Assets MNPR (Monopar Corp)|INBX - Aggregate Company Assets|Total Business Assets I-Mab Biopharma Co., Ltd. IMAB|FENC (Fennec Pharmaceuticals Inc.) - Company Total Assets|HRTX: Company Assets|Aggregate Company Assets Nuvectis NVCT|Coherus BioSciences, Inc. (CHRS) - Aggregate Asset Value|CRBP (Corbus Pharmaceuticals) - Company Total Assets|Company Total Assets CRDF|Aggregate Company Assets BeyondSpring (BYSI)|Aggregate Company Assets bioatla.com BCAB|Cumulative Company Assets Lixte Biotechnology Holdings|Citius Pharmaceuticals Inc. - Aggregate Asset Value|CLRB (Cellectar Biosciences) - Aggregate Company Assets|BLRX: Company Assets|Aggregate Company Assets Can-Fite BioPharma Ltd.|Aprea Therapeutics, Inc. (APRE) - Total Business Assets|Company Total Assets KZIA|Cumulative Company Assets SLXN|NuCana plc - Aggregate Company Assets|Company Assets CMRX (chimerix.com)|Aggregate Company Assets Cyclacel CYCC|G1 Therapeutics Inc. - Aggregate Company Assets|KTRA (Kintara) - Aggregate Company Assets|ONCT - Company Assets|Company Total Assets PRTG (Portage Biotech Inc.)